PCVX241115C115000
- 0.55
- 0.000.00%
Vaxcyte Newsroom
Vaxcyte Gets FDA Breakthrough Therapy Designation for Its Pneumococcal Disease Treatment
Vaxcyte Announces FDA Clearance for VAX-31 Infant Phase 2 Study and Breakthrough Therapy Designation for Adult Phase 3 Study
Express News | Vaxcyte Inc: Expects to Initiate Vax-31 Infant Phase 2 Study by End of January 2025
Express News | Vaxcyte Inc: Vax-31 Infant Indication: Investigational New Drug Application Cleared by FDA
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
Express News | Vaxcyte Provides Positive Regulatory Updates on Vax-31 Pediatric and Adult Programs
We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
Vaxcyte, Inc. Navigates AI Risks Amidst Regulatory and Ethical Challenges
BofA Securities Maintains Vaxcyte(PCVX.US) With Buy Rating
Cantor Fitzgerald Reiterates Overweight on Vaxcyte
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $135
BTIG Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $160
Needham Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $140
Express News | Vaxcyte Inc : Jefferies Raises Target Price to $146 From $129
Decoding Vaxcyte Inc (PCVX): A Strategic SWOT Insight
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Announces Target Price $135
Vaxcyte's Promising Clinical Advances and Strategic Plans Drive Buy Rating With $135 Price Target
Vaxcyte GAAP EPS of -$0.83 Beats by $0.31
Vaxcyte | 10-Q: Q3 2024 Earnings Report
Vaxcyte: $3.3 B in Cash, Cash Equivalents and Investments as of Sept 30,, Includes $1.4B From Sept. Offering>PCVX